Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
Type:
Application
Filed:
November 24, 2014
Publication date:
May 28, 2015
Inventors:
Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
Type:
Application
Filed:
November 30, 2012
Publication date:
May 28, 2015
Inventors:
Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
Abstract: Disclosed is a process in which a recombinant organism, such as a yeast, expressing a heterologous S-adenosylmethionine (SAM)-dependent methyl halide transferase (MHT) protein is combined with a halide and a carbon source in a cultivation medium under conditions in which methyl formate is produced. The cell may genetically modified to express methyl formate synthase, methanol dehydrogenase and/or hydrolytic dehalogenase at levels higher than a cell of the same species that is not genetically modified. The methyl formate may be collected and used in a variety of applications. The halide may be chlorine, bromine or iodine.
Type:
Grant
Filed:
July 22, 2010
Date of Patent:
May 26, 2015
Assignee:
The Regents of the University of California
Abstract: A recombinant micro-organism producing resveratrol by a pathway in which phenylalanine ammonia lyase (PAL) produces trans-cinnamic acid from phenylalanine, cinnamate 4-hydroxylase (C4H) produces 4-coumaric acid from said trans-cinnamic acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA, or in which L-phenylalanine- or tyrosine-ammonia lyase (PAL/TAL) produces 4-coumaric acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA. The micro-organism may be a yeast, fungus or bacterium including Saccharomyces cerevisiae, E. coli, Lactococcus lactis, Aspergillus niger, or Aspergillus oryzae.
Type:
Grant
Filed:
April 17, 2008
Date of Patent:
May 26, 2015
Assignee:
Evola SA
Inventors:
Michael Katz, Hans Peter Smits, Jochen Förster, Jens Bredal Nielsen
Abstract: Microbial biosensors that generate gas outputs in hard-to-image materials using exogenous methyl halide transferase (MHT) genes. By varying the promoter that is fused to the MHT gene, biosensors for different triggers can be made.
Type:
Application
Filed:
October 10, 2014
Publication date:
May 21, 2015
Inventors:
Jonathan J. SILBERG, Caroline A. MASIELLO, Hsiao-Ying CHENG
Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: Described is a method for generating conjugated dienes through a biological process. More specifically, the application describes a method for producing conjugated dienes (for example butadiene, isoprene or dimethylbutadiene) from light alkenols via enzymatic dehydration, in particular by making use of an alkenol dehydratase.
Abstract: This invention relates generally to nucleic acid sequences encoding proteins that are related to the presence of seed storage compounds in plants. More specifically, the present invention relates to Arabidopsis thaliana, Brassica napus, Glycine max and Oryza sativa nucleic acid sequences encoding sugar and lipid metabolism regulator proteins and the use of these sequences in transgenic plants. In particular, the invention is directed to methods fir manipulating sugar-related compounds and for increasing oil level and altering the fatty acid composition in plants and seeds. The invention further relates to methods of using these novel plant polypeptides to stimulate plant growth and/or to increase yield and/or composition of seed storage compounds.
Abstract: The present invention relates to variants with improved activity in an amide-bond reaction. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.
Type:
Application
Filed:
June 14, 2013
Publication date:
May 21, 2015
Applicant:
SCRIPPS KOREA ANTIBODY INSTITUTE
Inventors:
Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
Abstract: The present invention relates to variant endoglucanases having improved thermoactivity, improved thermostability, and improved viscosity reduction activity over wild-type M. thermophila endoglucanase.
Type:
Application
Filed:
November 14, 2014
Publication date:
May 21, 2015
Inventors:
XIYUN ZHANG, SACHIN PATIL, JIE YANG, ISH KUMAR DHAWAN
Abstract: Provided is a genetically engineered yeast cell with lactate production capacity, including an enzyme that catalyzes conversion of acetaldehyde to acetyl-CoA and an enzyme that catalyzes conversion of pyruvate to lactate, which activities are increased compared to a parent cell of the yeast cell, as well as a method of producing the genetically engineered yeast cell and method of producing lactate using the genetically engineered yeast cell.
Type:
Application
Filed:
November 14, 2014
Publication date:
May 21, 2015
Inventors:
Jiyoon SONG, Changduk KANG, Joonsong PARK, Sungsoo KIM, Youngkyoung PARK, Sunghaeng LEE, Soyoung LEE, Juyoung LEE, Kwangmyung CHO, Wooyong LEE
Abstract: The object of the present invention is to provide Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides a transformant transformed with a gene for Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing such a transformant.
Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
Abstract: A genetically engineered yeast cell capable of producing lactate having increased TPI activity, a method of preparing the yeast cell, and a method of producing lactate by using the yeast cell.
Type:
Application
Filed:
November 13, 2014
Publication date:
May 21, 2015
Inventors:
Juyoung Lee, Changduk Kang, Soyoung Lee, Youngkyoung Park, Jiyoon Song, Seunghyun Lee, Kwangmyung Cho
Abstract: The disclosure relates to a method for enhancing the biosynthesis and/or secretion of sapogenins in the culture medium of plant and microbial cell cultures. Further, the disclosure also relates to the identification of novel genes involved in the biosynthesis of sapogenin intermediates, as well as to novel sapogenin compounds.
Type:
Application
Filed:
May 13, 2013
Publication date:
May 21, 2015
Inventors:
Alain Goossens, Tessa Moses, Jacob Pollier, Lorena Almagro Romero
Abstract: The invention relates to a polypeptide having a mutation at one or more position corresponding to T219 of SEQ ID NO: 55, wherein the polypeptide has at least 50% sequence identity with SEQ ID NO: 55, and wherein the polypeptide has permease activity.
Type:
Grant
Filed:
October 11, 2011
Date of Patent:
May 19, 2015
Assignee:
DSM IP ASSETS, B.V.
Inventors:
Hendrik Wouter Wisselink, Antonius Jeroen Adriaan Van Maris, Jacobus Thomas Pronk, Paul Klaassen, Rene Marcel De Jong
Abstract: DNA encoding a monomeric variant of red fluorescent protein eqFP611 comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.
Type:
Grant
Filed:
January 27, 2014
Date of Patent:
May 19, 2015
Assignee:
Universitat Ulm
Inventors:
Jörg Wiedenmann, Simone Kredel, Franz Oswald, Gerd Ulrich Nienhaus
Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Application
Filed:
November 12, 2014
Publication date:
May 14, 2015
Inventors:
Nicholas J. Agard, Oscar Alvizo, Melissa Ann Mayo, Stefanie Ng Minor, James Nicholas Riggins, Jeffrey C. Moore
Abstract: The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein. The fusion protein significantly enhances the skin penetration and skin retention of the physiologically active protein while maintaining or enhancing the ability of the physiologically active protein to synthesize a material showing physiologically active effects. Thus, it can be widely used as an active ingredient in functional cosmetic compositions and pharmaceutical compositions for external skin use.
Type:
Application
Filed:
April 30, 2014
Publication date:
May 14, 2015
Inventors:
Seol Hoon Lee, Sang Hwa Lee, Nae Gyu Kang, Eu Gene Hur
Abstract: The present invention relates to isolated polypeptides having xanthan degrading activity, catalytic domains and polynucleotides encoding the polypeptides and catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides and catalytic domains.
Type:
Application
Filed:
May 7, 2013
Publication date:
May 14, 2015
Inventors:
Dorotea Raventos Segura, Peter Fischer Halin, Anders Viksoe-Nielsen, Lars Anderson, Martin Simon Borchert, Leigh Murphy, Astrid Boisen, Lorena G. Palmén, Kenneth Jensen, Carsten Sjoeholm, Tine Hoff, Charlotte Blom
Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
Type:
Application
Filed:
November 18, 2014
Publication date:
May 14, 2015
Inventors:
Leon F. GARCIA-MARTINEZ, Ann Elisabeth CARVALHO JENSEN, Katie OLSON, Benjamin H. DUTZAR, Ethan W. OJALA, Brian R. KOVACEVICH, John A. LATHAM, Jeffrey T.L. SMITH
Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.
Type:
Application
Filed:
September 19, 2012
Publication date:
May 14, 2015
Inventors:
Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
Abstract: The present invention relates to compositions and methods for delivering lysosomal proteins. The compositions and methods described herein permit the targeted delivery of exogenous lysosomal proteins to cell surface proteins that allow their internalization via non-clathrin pathways. The present invention further relates to the use 10 of the compositions and methods for enzyme replacement therapy of lysosomal storage diseases. Nucleic acids, recombinant cells and kits useful for making and using the compositions of the invention are also provided.
Type:
Application
Filed:
October 16, 2014
Publication date:
May 14, 2015
Inventors:
Silvia Muro Galindo, Vladimir R. Muzykantov, Edward Howard Schuchman
Abstract: The present invention relates to a cell based genomic Recorded Accumulative Memory (geRAM) system (also referred to herein as Genomically Encoded Memory (GEM)) for recoding data (i.e., changes in nucleic acid sequences in cellular DNA in response to physical and/or chemical signal(s)) from the cellular environment.
Type:
Application
Filed:
November 7, 2014
Publication date:
May 14, 2015
Inventors:
Joseph M. Jacobson, Noah Jakimo, Naama Kanarek, David Sabatini
Abstract: The present invention provides for a system for increasing the production of a compound using an artificial positive feedback loop (APFL). In some embodiments, the system diverts a compound produced in a first metabolic pathway into a second metabolic pathway in order to produce a compound of interest.
Type:
Application
Filed:
January 27, 2015
Publication date:
May 14, 2015
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: Compositions useful for reducing the risk of, preventing, and/or treating S. pyogenes (GAS) infections which comprise combinations of GAS antigens, nucleic acid molecules encoding the antigens, or antibodies which specifically bind to the antigens.
Type:
Application
Filed:
November 13, 2014
Publication date:
May 14, 2015
Inventors:
Guido GRANDI, Immaculada MARGARIT Y ROS, Sabrina CAPO, Giuliano BENSI, Andrea Guido Oreste MANETTI
Abstract: The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: Methods for increasing C18 to C20 elongation conversion efficiency and/or ?4 desaturation conversion efficiency in long-chain polyunsaturated fatty acid [“LC-PUFA”]-producing recombinant oleaginous microbial host cells are provided herein, based on over-expression of acyl-CoA:lysophospholipid acyltransferases [“LPLATs”] (e.g., Ale1, LPAAT, LPCAT). Production host cells and oils produced by the methods of the invention are also claimed.
Type:
Grant
Filed:
August 2, 2013
Date of Patent:
May 12, 2015
Assignee:
E I du Pont de Nemours and Company
Inventors:
Narendra S Yadav, Hongxiang Zhang, Quinn Qun Zhu
Abstract: Nucleic acid molecules from cannabis has been isolated and characterized and encode polypeptides having aromatic prenyltransferase activity. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Type:
Application
Filed:
November 6, 2014
Publication date:
May 7, 2015
Inventors:
Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
Abstract: The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
Abstract: The present invention provides herein a polynucleotide sequence encoding the tubby-like protein, CaTLP1, from chickpea (Cicer arientium L.) that is responsive to abiotic stress and is involved in plant growth and development. Further, the recombinant DNA construct and recombinant vector comprising the polynucleotide sequence encoding CaTLP1, host cell comprising the recombinant vector and a process for producing a transgenic plant that expresses the CaTLP1 protein are also provided herein.
Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.
Abstract: A microorganism with improved acid-resistance. A microorganism capable of efficiently producing 3-HP, and methods for producing an organic acid.
Type:
Application
Filed:
November 3, 2014
Publication date:
May 7, 2015
Inventors:
Juyoung Lee, Hyunmin Koo, Jaechan Park, Jieun Kim, Jinha Kim, Joonsong Park, Soonchun Chung, Byungkwan Cho
Abstract: Provided are isolated polypeptides having glucoamylase activity, catalytic domains, and polynucleotides encoding the polypeptides, catalytic domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains.
Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
Type:
Application
Filed:
June 6, 2013
Publication date:
May 7, 2015
Inventors:
Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.
Type:
Application
Filed:
July 8, 2014
Publication date:
May 7, 2015
Inventors:
Markus ZWECKSTETTER, Pinar KARPINAR, Christian GRIESINGER
Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
Type:
Application
Filed:
July 2, 2014
Publication date:
May 7, 2015
Inventors:
Oliver HILL, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
Abstract: A simple and inexpensive method for selectively culturing a microorganism which method makes it possible to selectively culture a microorganism of interest even without using a sterilization operation or an antibiotic substance is provided. The method according to the present invention selectively culturing a microorganism includes the step of culturing, in a culture medium containing phosphorous acid as a sole phosphorous source, a recombinant microorganism into which a phosphite dehydrogenase gene has been introduced.
Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
Abstract: A high flux in conversion of pyruvate to acetolactate was achieved in yeast through expression of acetolactate synthase in the cytosol in conjunction with reduction in pyruvate decarboxylase activity. Additional manipulations to improve flux to acetolactate are reduced pyruvate dehydrogenase activity and reduced glycerol-3-phosphate dehydrogenase activity. Production of compounds having acetolactate as an upstream intermediate benefit from the increased conversion of pruvate to acetolactate in the described strains.
Type:
Application
Filed:
December 16, 2014
Publication date:
May 7, 2015
Inventors:
LARRY CAMERON ANTHONY, LORI ANN MAGGIO-HALL
Abstract: The invention relates to a method for the synthesis of diacids of general formula ROOC—(CH2)n—(CH?CH)a—(CH2)mCOOR1 in which n and m are identical or different and each represent an integer such that their sum is between 6 and 15, a is an index of 0 or 1, and R and R1 are H or an alkyl radical with 1 to 4 carbon atoms, from long-chain mono-unsaturated natural fatty acids or esters having at least 10 adjacent carbon atoms per molecule of the general formula CH3—(CH2)p—CH?CH—(CH2)q—COOR, p and q, being identical or different and representing indices between 2 and 11, wherein said method comprises the first step of oxidizing by fermentation said natural fatty acid or ester, using a microorganism, such as a bacterium, a yeast, or a fungus, into at least one unsaturated dicarboxylic acid or dicarboxylate, the second step of submitting the product from the first step to a metathesis crossed with a compound of formula R2OOC—(CH2)x—CH?CH—R3, in which R2 is H or an alkyl radical with 1 to 4 carbon atoms, x is 0 or 1 or